Cingulate Inc. (CING): Net earnings per share for the last 12 months

Symbol and logo of brand cingulate.com (CING)

Cingulate Inc. develops therapies for ADHD and anxiety utilizing extended-release methods. Net income per share TTM demonstrates fundamental stability, where the parameter value equals -3.64. CTR patents and strict FDA oversight serve as business protections, while growth relies on the collection of clinical test data within the R&D platform.

CING (Cingulate Corp) Net earnings per share for the last 12 months history from 07/04/2022 to 11/10/2026

Analytical breakdowns and data insights for company Cingulate Inc (CING)

- current quotes and average value forecast:
Price Chart Cingulate Corp|CING - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Cingulate Inc.|CING - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Cingulate|CING - Company Net Assets|Market Capitalization to Book Value Ratio cingulate.com|CING - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity Cingulate Inc.|CING - Long-Term Liabilities to Capital|Short-Term Debt to Capital Cingulate Corp|CING - Company Total Debt|Debts to Book Capitalization Cingulate Inc.|CING - Long-Term Debt Volume|Company Short-Term Debt Cingulate|Quick Ratio cingulate.com
- net income and valuation multiples indicators:
CING - Annual Net Income|Future Profit Cingulate Inc.|CING - P/E Multiple|Future Price to Earnings Cingulate Corp|CING - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Cingulate Inc.|CING - Operating profit EBITDA|Net earnings per share for the last 12 months Cingulate|CING - Earnings per share for the last four quarters|Quarterly EPS earnings growth cingulate.com|CING - Earnings per share growth rate in current year|Expected earnings per share growth for next year Cingulate Inc.
Initial company analysis:cingulate.com (CING)
Mass-produced product of Cingulate Inc

Amid market uncertainty, investors prioritize seeking assets with proven returns. This metric measures net income distributed per share, allowing for an assessment of real capital efficiency regardless of the issuance volume. By analyzing the net income per share over the last 12 months, one can determine the business's resilience to borrowing costs. For Cingulate Inc. (CING), this indicator reflects financial results in the absence of heavy capital expenditures. Outsourcing production and testing makes profit dynamics more sensitive to the operational successes of the scientific team.

Competitors of Cingulate Inc.

ALKS - Earnings per share for the last twelve months|Net earnings per share for the last four quarters avadel.com AVDL|ATAI (atai Life Sciences) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months GH Research plc (GHRS)|MNMD (MindMed Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months COMPASS Corp (CMPS)|Net earnings per share (EPS TTM) LBRX|DRUG (brightmindsbio.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Vanda Pharmaceuticals Inc. VNDA|Cybin Inc (CYBN) - Net earnings per one share for the last twelve months|Alto Neuro - Net earnings per share (EPS TTM)|NRx Pharmaceuticals, Inc (NRXP) - Net earnings per share for the last 12 months|SILO: Net earnings per share (EPS TTM)|CPHI - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Clearmind Medicine|Earnings per share for the last 12 months PBM (Psyence Biomedical Ltd)|Net earnings per share (EPS TTM) SPRC|Seelos Therapeutics Inc (SEEL) - Net earnings per share for the trailing year|Virpax Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) karunatx.com KRTX